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Background: Reliable central venous access (CVC) is essential for hematology–oncology patients since frequent
puncture of peripheral veins—e.g., for chemotherapy, antibiotic administration, repeated blood sampling, and
monitoring—can cause unacceptable pain and psychological trauma, as well as severe side effects in cases of
extravasation of chemotherapy drugs. However, CVC lines still carry major risk factors, including thrombosis,
infection (e.g., entry site, tunnel, and luminal infections), and catheter dislocation, leakage, or breakage.
Methods: Here we performed a retrospective database analysis to determine the incidence of CVC-associated
thrombosis in a single-center cohort of 448 pediatric oncologic patients, and to analyze whether any subgroup of
patients was at increased risk and thus might benefit from prophylactic anticoagulation.
Results: Of the 448 patients, 269 consecutive patients received a CVC, and 55 of these 269 patients (20%) also had
a thrombosis. Of these 55 patients, 43 had at least one CVC-associated thrombosis (total number of CVC-associated
thrombosis: n = 52). Among all patients, the median duration of CVC exposure was 464 days. Regarding exposure
time, no significant difference was found between patients with and without CVC-associated thrombosis. Subclavia
catheters and advanced tumor stages seem to be the main risk factors for the development of CVC-associated
thrombosis, whereas pharmacologic prophylaxis did not seem to have a relevant impact on the rate of thrombosis.
Conclusions: We conclude that pediatric surgeons and oncologists should pay close attention to ensuring optimal
and accurate CVC placement, as this appears the most effective tool to minimize CVC-associated complications.
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For hematology-oncology patients, reliable central venous
access (CVC) is essential since frequent puncture of per-
ipheral veins—e.g., for chemotherapy, antibiotic adminis-
tration, repeated blood sampling, and monitoring—can
cause unacceptable pain and psychological trauma, as well
as severe side effects in cases of extravasation of chemo-
therapy drugs [1]. In 1973, the percutaneous catheter
made of silicone rubber was first introduced for central
vein access [2], and totally implantable access ports were* Correspondence: Wiegering_V@ukw.de
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article, unless otherwise stated.introduced in 1982 [3]. Since 1992, the European chil-
dren’s cancer study group has recommended CVC, espe-
cially the port system, as the preferred device for pediatric
patients because of its longer life expectancy, easy care,
and improved patient acceptance [4,5]. Today, CVCs are
the gold standard in pediatric oncology departments.
However, they still carry several associated risks, including
thrombosis; infection (entry site, tunnel infection, and
luminal infection); and catheter dislocation, leakage, or
breakage [4,6].
Catheter-associated thromboses remain a frequent com-
plication, and there are ongoing scientific discussions
about routine administration of prophylactic anticoagu-
lation in pediatric patients with malignancies. On one
hand, CVCs may contribute to the risk of thrombophilia.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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hemorrhage may be further aggravated by prophylactic
anticoagulation. Cancer itself is a well-known risk factor
for thrombosis development through various simultan-
eous mechanisms involving venous stasis (immobilization
and compression), endothelial damage (cancer-associated
and from surgery, chemotherapy, and central venous cath-
eters), and blood hypercoagulation (from expression of tis-
sue factors and cancer-associated pro-coagulants, and
associated with therapy using hormones, asparaginase,
corticosteroids, etc.) [7,8]. Among adults, the incidence of
venous thromboembolism (VTE) is approximately six-fold
higher in patients with cancer and up to 10-fold higher
in those patients receiving chemotherapy [9]. During
therapy, approximately 20% of adult cancer patients will
develop VTE, and this occurrence is an independent
prognostic factor representing the second leading cause
of mortality [7,10]. However, data in the pediatric cancer
population remain sparse and may be different from the
adult population, as patient age and therapy protocol in-
tensity are important contributing factors for throm-
bosis in healthy individuals [11,12].
There are currently no guidelines regarding antithrom-
botic prophylaxis in children with malignancy and CVC.
Daily instillation of heparin solution into the catheter
lumen is commonly performed to prevent clotting of the
catheter tip, but no large controlled study has been
undertaken to assess the effectiveness of this procedure
in children with cancer. The present study aimed to
examine the incidence of CVC-associated thrombosis in
our study population (n = 448; from January 01, 2008
until December 31, 2012). We further analyzed whether
epidemiologic characteristics (such as tumor entity and
patient age and gender) and treatment-related charac-
teristics (such as chemotherapy drug, duration, and
position) influenced the frequency of thrombosis. Fi-
nally, we investigated whether any specific subgroup
appeared to have an increased risk of central venous
access thrombosis, and thus might particularly benefit
from prophylactic anticoagulation.
Methods
Patients and data collection
We performed a systematic search of our electronic pa-
tient database for children who were newly diagnosed
with malignancy between January 01, 2008 and December
31, 2012. Our research has adhered to the STROBE
guidelines for observational studies. Within this popula-
tion, we further searched for patients who also had cen-
tral venous access, and suffered from thrombosis or
vascular complications unrelated to admission or dis-
charge diagnosis. As in the German health system every
diagnosis is encoded according the ICD-10 catalog wesearched for I80-82. These ICD10-codes include all kind
of thrombosis of the venous system. We performed
chart review of all patients, who were identified by this
search. Patients were excluded if their reported throm-
bosis or venous vascular complications were not related
to the central venous access (Figure 1). CVC-associated
thrombosis was defined as a thrombus at the catheter
side which radiologic evidence (by ultrasound, echocar-
diography or X-ray examination). The clinical evidence
of catheter obstruction was facultative, but was present
in over 95% of patients.
In accordance with institutional guidelines, informed
consent for chart review for retrospective studies was
obtained from all patients. Two reviewers (the two first
authors) independently extracted epidemiological data
(e.g., gender, age, underlying disease, family history, ther-
apy and medication in the preceding 20 days, and catheter
details), clinical presentation at the time of thrombosis
and during hospital stay, and laboratory findings (e.g., blood
gas analysis, full blood count, and coagulation parameters).
We could obtain data of all identified patients, so that we
did not have to exclude patient for incomplete or missing
data. The study was approved by the ethics committee of
the University Hospital Würzburg (study #133/04).Surgical methods
Following routine protocol, all oncologic patients with an
indication for CVC implantation received a port-a-cath. A
Hickman catheter was used only in patients undergoing
more intensive therapy or with an indication for stem cell
transplantation. All CVC implantations were performed
under general anesthesia in the Division of Pediatric
Surgery. After disinfection, a 3- to 4-cm skin incision
was made in the sulcus deltoideus. Subcutaneous tissue
was dissected, and the cephalic vein was prepared. If im-
plantation in the cephalic vein was not possible, the
vena jugularis externa or interna was prepared instead.
Following venotomy, the catheter was inserted and the
position checked by intraoperative chest radiography.
The catheter was fixed when the tip was located between
the junction of the superior caval vein and the right
atrium. Catheters were revised immediately in every sin-
gle patient if the location was not between the junction
of the superior caval vein and the right atrium as it is
known to be the most evident risk factor for the devel-
opment of CVC-associated thrombosis. Postoperatively,
the catheter tip location was re-checked by chest radi-
ography, blood regurgitation was confirmed, and then
the catheter was put into use. The catheter was kept filled
with 3 to 5 mL of heparinized saline solution (100 U/mL)
after each completion of blood sampling or drug injection.
For port systems, port needles were changed under sterile
conditions every 14 days.
Figure 1 Flow chart of study populations.
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The data were analyzed using JMP® (version 5.0, software
SAS, Camarillo, USA). The analyzed parameters are
expressed as mean ± standard error of the mean (SEM)
unless otherwise indicated. After data abstraction, the
Student’s t-test was used for comparative analysis of
continuous variables. For statistical analysis, influences
of age and gender were ruled out using the exact U
test, Fisher’s test, and Puri and Sen’s two-way ranked
ANOVA. In all statistical applications, P < 0.05 was
considered significant.
Results
Over the 5-year study period, we identified 448 patients
with newly diagnosed malignancy (Figure 1). Of these
patients, 269 received a central venous access. Prior to
CVC implantation, patients were screened for APC resist-
ance, protein S and protein C deficiency, and dysfibrino-
genemia. In case of positive findings (one APC resistance,
one protein S deficiency, and one protein C deficiency)
prophylactic anticoagulation with LMWH was performed
during the whole period of CVC-placement, if platelet
count was above 40/nL.
Systematic searching of all 269 patients with newly di-
agnosed malignancy and CVC identified 55 patients with
thrombosis. Of these 55 patients, 43 had central venous
access-related thrombosis, with some patients experiencing
CVC-associated thrombosis twice or more, resulting in a
total of 52 events in the 43 patients. Table 1 and Figure 2
present the clinical characteristics and distributions oftype of disease, CVC-associated thrombosis, and type
of CVC.
First episode of CVC-related thrombosis
The group of 43 patients with CVC-associated throm-
bosis was further analyzed. They included 24 males and
19 females, with a mean age of 9.39 ± 0.95 years (range:
6 months to 18 years). The median time from CVC in-
sertion until catheter-associated thrombosis was 202 ±
32 days, and the median time since diagnosis until
catheter-associated thrombosis was 344 ± 53 days. The
median CVC follow-up duration was 603 ± 447 days.
Twelve patients underwent the CVC insertion operation
twice and three patients underwent the operation three
times. There was no dependency to the tumor entity. Pa-
tients with CVC-associated thrombosis had a mean of
1.6 ± 0.9 catheters inserted. Female patients were signifi-
cantly older than male patients at the time of thrombosis
(11.3 ± 1.4 vs. 7.2 ± 1.2; p < 0.05), and the duration from
catheter implantation until thrombosis was significant
longer in females than males (501 ± 73 vs. 215 ± 66 days;
p < 0.01). The number of implanted catheters and the
thrombosis recurrence rates did not differ with regard to
gender or age. Important to note, we did not observed a
clinical apparent post-thrombotic syndrome in our patients
after CVC-associated thrombosis.
The catheter access veins used in the 52 CVC implanta-
tions with CVC-associated thrombosis were as follows:
17 vena cephalica, 11 vena jugularis externa, 11 vena sub-
clavian, 9 vena jugularis interna, 2 vena cava superior, 1





























7 6 20 17 13%
Leukemia 81 79 (98%) 20 17 25 22 38%
Solid
Tumor
116 72 (62%) 5 3 7 4 10%
CNS
Tumor
168 68 (40%) 14 12 20 18 27%
Others 48 15 (31%) 6 5 40 33 12%
Total 448 269 52 43 100%
Abbreviations: CNS central nervous system, CVC central venous catheter.
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catheters were placed on the left side, and 35 on the right
side.
CVC-associated thrombosis occurred in 17 patients
with leukemia (n = 20), 6 with lymphoma (n = 7), 3 with
solid tumors (n = 5), 12 with central nervous system
(CNS) tumors (n = 14), and 5 with other hematologic-
oncologic diagnoses, including severe aplastic anemia
(SAA), myelo-dysplastic syndrome (MDS), and hemo-
phagocytic lymphohistiocytosis (HLH) (Figure 1). The
different tumor entities were not associated with signifi-
cant differences regarding clinical characteristics (age,
thrombophilia, type of catheter, or catheter infections)
or treatments performed within the 20 days preceding
the appearance of thrombosis (antibiotics, corticoste-
roids, and chemotherapy in general or surgical ap-
proaches), except for the use of asparaginases in patients
with leukemia. Even if it failed to reach statistical signifi-
cance it is mentionable that in our study patients with
solid tumors had a lower incidence rate of CVC-
associated thrombosis. This may have implications for
prophylactic treatment and has to be reevaluated in a
greater cohort in future.
Eight of the 17 leukemia patients with CVC-associated
thrombosis had received asparaginase within the 20 pre-
ceding days. Asparaginase is known to promote throm-
bophilia by interfering with the coagulation system.
Thus, as a preventive measure, each patient undergoing
asparaginase treatment had received prophylactic antic-
oagulation treatment until their coagulation pattern nor-
malized. Despite these measures, 40% (8/20) of the
catheter-associated thrombosis in the leukemic patients
developed thrombosis in the temporal context of aspara-
ginase medication.
The different tumor entities significantly differed with
regard to the use of prophylactic anticoagulation with
heparin derivate at the time of thrombosis. Prophylactic
anticoagulation was used in 43% of lymphoma patients,35% of leukemia patients, 28% of CNS tumor patients,
and 0% of solid tumor patients (Figure 2D; P < 0.05 for
between all tumor entities) at the time of thrombosis de-
velopment. In each case, therapeutic anticoagulation
with heparin derivate was administered for a median of
9 days (range: 7 to 14 days).
Due to the high inter-individual variety, we could not
identify a time-point of increased risk after implantation.
Port systems showed an earlier peak of thrombosis oc-
currence than Hickman catheters; however, the overall
prevalence of CVC-associated thrombosis was compar-
able (Figure 3). Nearly 50% of CVC-associated throm-
bosis events occurred in ports within the first 100 days
after insertion, while Hickman-associated thrombosis on
average occurred substantially later at about 230 days
after implantation (Figure 3B).
We also found that the time from CVC implantation
until thrombosis differed between the different tumor
entities. Analyzing the time from diagnosis (in total: 344
± 53 days) or the time from implantation of central ven-
ous access until thrombosis (in total 202 ± 126 days), we
observed earlier thrombotic complications in patients
with hematological diseases (leukemia: 199 ± 41 days;
lymphoma: 125 ± 64 days) and solid tumors (137 ± 80 days)
compared to patients with brain tumors (253 ± 61 days).
However, due to the small patient numbers, the detected
differences failed to reach statistical significance and in
addition scatter range was relatively big. However, it seems
to be an interesting issue to study as a potential marker of
risk and should be studied in an adequate cohort.
Recurrent CVC-related thrombosis
After thrombosis, 75% of patients received prophylactic
anticoagulation if platelet count exhibited above 40/nL.
Among these patients, 16% developed a re-thrombosis
despite prophylactic anticoagulation. In the lymphoma
group, 42% of patients with thrombosis required cath-
eter removal because of re-thrombosis or dysfunction,
Figure 2 Thrombosis and CVC distributions. (A) The proportion of patients with CVC according to the different tumor entities. (B) The
distribution of port and Hickman access systems among the different patient groups with CVC. (C) The distribution of port and Hickman access
within the patient subpopulation with thrombosis. (D) The proportion of prophylactic anticoagulation at the time of thrombosis according to the
different tumor entities. (E) The distribution of the different malignancies with regard to the whole cohort (column 1), the whole patient group
with central venous access (column 2), and the patient group with central venous access and CVC-associated thrombosis (column 3). (F) The
proportion of patients with thrombosis according to the different age subgroups.
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removed in the other groups. We did not find other risk
factors for re-thrombosis regarding clinical characteris-
tics in our group. However, it may be limited by the
small subgroup and should be re-evaluated in a bigger
cohort.
Comparison between patients with and without
CVC-associated thrombosis
When comparing data within the whole patient cohort,
which received central venous access (n = 269), the venasubclavia catheters (45/269) showed the highest incidence
of thrombosis (11 patients with 45 implanted catheters;
24%), followed by vena jugularis externa and vena cepha-
lica catheters (17 thrombosis/128 implanted catheters;
13%). No differences were found between right- and
left-sided catheters.
Furthermore, we did not find significant differences
with regard to gender, age, exposure time of CVC, or
treatment with high-dose steroids or asparaginase when
comparing the CVC-associated thrombosis group with
the group of patients with CVC and no CVC-associated
Figure 3 Days from CVC implantation until appearance of CVC-associated thrombosis. (A) The days on which thrombosis occurred for
each patient. (B) The days on which thrombosis occurred in patients with port (red) and Hickman (green) catheters. Analysis of the complete
follow-up data revealed no significant differences. Analysis of the time-point at which 50% of thrombosis occurred, revealed that port systems
reached a peak of thrombosis events earlier than that with Hickman catheters (P < 0.01).
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heparin use in both groups we did not find a significant
differences (68/269 = 25.3% vs. 14/52 = 26.9%). The dur-
ation of prophylactic heparin therapy was dependent from
co-medication, therapy and the individual risk profile.
Among patients with CVC-associated thrombosis, pro-
thrombin time (89 ± 2.4%), aPTT (34.8 ± 2.5 s), d-dimers
(1.6 ± 0.1 mg/L), fibrinogen (2.95 ± 0.2 mg/L), antithrombin
III (91.7 ± 3.65%), and platelet count (246000 ± 21000/μL)
were within the expected ranges (immediately before catheterinsertion and at the time of thrombosis (shown data)) and
did not differ significantly from those patients without
CVC-associated thrombosis at comparable time points.
Not surprisingly, the surviving patients with progressive
disease exhibited significantly more catheter-associated
thrombotic events than the patients in complete remission
(p < 0.05). This observation was even pronounced in pa-
tients who died from disease: they had a higher incidence
of catheter-associated thrombosis than patients with stable
disease and patients in complete remission (p < 0.01).
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Central venous catheters (CVC) are a well-established
and important component of care for pediatric hematology–
oncology patients. However, complications are common
and must be monitored carefully in order to prevent se-
vere side effects. In this context, one major concern is the
prevention of catheter-associated thrombosis. Although
the prevalence of deep venous thrombosis and/or throm-
botic line occlusion has not yet been determined, these
events may be more frequent in children with malignancy
and CVC [13,14] than in a healthy pediatric cohort. Solid
data are lacking with regard to the incidence and efficient
prevention of catheter-associated thrombosis in the
pediatric population. In the review of existing data
CVC-associated thrombosis are reported in a big range
between 3% up to 40% [15-19]. However, study settings
and results are not uniform and valuable data for inci-
dence and risk factors are lacking in the pediatric co-
hort. Especially pediatric cancer patients seem to have
an increased risk for CVC-associated thrombosis com-
pared with non-cancer patients, who received a central
venous access [17]. Therefore, it is of special interest in
this patient cohort to define risk factors to be able to
prevent effectively thrombosis development.
There remains some controversy regarding the best
supportive care and treatment plans for pediatric cancer
patients with CVC. Thus, an individual investigator may
have to rely on personal experience and individual risk–
benefit assessment when deciding about prophylactic and
therapeutic anticoagulation.
Clinical manifestations due to venous thrombi may be
less frequent than actual events. A number of studies have
assessed the incidence of VTE associated with long-term
CVC in adult cancer patients, with values ranging from
0.3 to 20% [20,21]. In a study of 72 consecutive autopsy
cases, Raad et al. [22] reported that 38% of catheterized
veins exhibited a fibrin layer on the external surface of all
intravascular catheter segments and a mural thrombosis,
compared to only 1.4% of controlateral veins. Thus, it ap-
pears that these fibrin sleeve thromboses are likely a uni-
versal and clinically silent phenomenon. It also seems
possible that if they are left untreated, and they persist and
grow, they could play an important role in the pathogen-
esis of thrombosis, infection, and patient outcome. Indeed,
several authors have proposed a relationship between
catheter-related thrombogenesis and infection [23], and
infections in immunosuppressed patients are a proven risk
factor for mortality [24,25].
In pediatric patients, especially in children below three
years of age, venous access is often complicated by small
vein diameter, particularly in cases of re-implantation.
Therefore, it is important to identify VTE risk factors, and
to understand how to best prevent catheter-associated
VTE. Authors have proposed a number of possible riskfactors for CVC-related VTE development, including
CVC biocompatibility, number of lumina, catheter tip
position, insertion site, CVC insertion techniques, previ-
ous CVC insertions and catheter-related complications
(mainly CVC malfunction or infections), and high platelet
count [21]. Throughout our study period, catheter care
was standardized and was performed by the same sur-
geons, oncologists, and nurses. The tip of a long-term
CVC was always located at the junction of the superior
caval vein and the right atrium, as correct positioning of
the distal catheter tip is associated with a significantly
lower rate of CVC-related thrombosis [21,26].
As reported in previous studies, in general subclavian
and jugular access is associated with a lower CVC-related
thrombosis incidence than a femoral or brachial access.
However, we confirmed that jugular and cephalica access
has a lower incidence of CVC-related thrombosis than
subclavian [21,27,28]. There is some controversy regarding
the optimal side for catheter insertion, with some authors
reporting that left-sided insertion correlates with an in-
creased risk of thrombotic complications [2]. We did not
detect this association in our small pediatric cohort; how-
ever, most of the patients had a right-sided catheter, and
venous access varied greatly. As in other reports, we found
no significant difference in the obstruction-free duration
of catheter use between correctly positioned port- and
Hickman-catheters [4,29]. Interestingly, the time of CVC-
associated thrombosis occurrence differed significantly
between port and Hickman catheters. Nearly 50% of
CVC-associated thrombosis events with ports occurred
within the first 100 days after insertion, whereas Hickman-
associated thrombosis events occurred significantly later at
an average of about 230 days after implantation (Figure 3B).
We suppose that the earlier peak may be due to the differ-
ent intensity of therapy—especially among hematologic
patients with a port and therapy- and disease-related alter-
ations of coagulation.
Among adult patients, specific malignancies such as
ovarian carcinoma or myeloma have been associated
with higher incidences of thromboembolia and catheter-
associated thrombosis. In the present retrospective ana-
lysis we did not identify any patient group as having a
higher incidence of CVC-associated thrombosis. How-
ever, the pathogenesis of CVC-associated thrombosis is
probably multifactorial, with thrombogenesis impacted
by CVC-associated features (such as tip position and side
of insertion) as well as patient features (such as platelet
count, cancer-related and therapy-related coagulation
cascade activation, and thrombophilic molecular abnor-
malities) [30]. However, we did find that patients who
underwent a more intensive chemotherapy—such as pa-
tients with hematologic malignancies or solid tumors—
presented with an earlier VTE occurrence compared to
patients with CNS tumors (166 ± 60 vs. 253 ± 61 days after
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cancer-related and therapy-related abnormalities of the
coagulation cascade to the occurrence of CVC-associated
VTE.
Since central venous access is necessary and we cannot
influence patient- and cancer-associated features, it is
important to discuss other potential options for reducing
the incidence of CVC-associated VTE. Hemostasis can
be influenced and improved by heparin, vitamin K antago-
nists, and new generation anticoagulation drugs. In cases
without blood regurgitation, mechanical problems must
be ruled out (e.g., needle and catheter tip position, and
catheter breakage or leakage). Treatment of catheter-
associated thrombosis with low-dose fibrinolytic agents,
such as streptokinase or urokinase, or with recombinant
tissue-type plasminogen activator can be attempted, as it
is known to be highly effective and safe in resolving the
catheter-related thrombus. Restoration of catheter patency
is possible with these agents in two-thirds of cases
[4,23,31]. This procedure may prevent re-implantation,
but will not prevent further growth of the fibrin layer
on the external surface of the intravascular catheter.
Additionally, a catheter occlusion does not exclude
(and may even elevate) the risk of further VTE, and
they are often asymptomatic, especially in cancer pa-
tients [32,33]. On the other hand, at the moment clin-
ical data could not show certain evidence, which
justified a prophylactic anti-coagulative treatment to
prevent silent and asymptomatic VTE, even in patients
with catheter obstruction.
CVC-related thrombosis is an important cause of mor-
bidity in cancer patients [20,34], and therefore many inves-
tigators have attempted to identify an effective prophylaxis
regimen [20,23]. The ongoing Thrombotect Study within
the ALL-BFM study group is working to address this im-
portant issue (J. Greiner, personal communication). Sur-
prisingly, the previously published literature does not
support the use of routine thromboprophylaxis for CVC in
cancer patients. In our cohort, thromboprophylaxis was
performed in patients who were considered to be at a high
risk of VTE based on their genetic risk profile, tumor site,
or use of asparaginase medication. However, the existing
literature contains no evidence supporting the routine use
of low-molecular-weight heparin (LMWH), low-dose or
adjusted-dose warfarin, continuous unfractionated heparin
(UFH), or fibrinolytics to prevent symptomatic CVC-
thrombosis [20].
One exception may be the treatment with asparaginase
used in leukemia and lymphoma treatment protocols.
Up to 25% of all thrombotic events are reported after
L-asparaginase infusion and during treatment with corti-
costeroids [35]. Among the leukemia patients with CVC-
associated VTE, 40% developed thrombosis within the
temporal context of asparaginase medication. It is wellknown that L-asparaginase may lead to an increased
risk of thrombosis [5], and this knowledge supports the
necessity of carefully monitoring patients with CVC
who are undergoing L-asparaginase and steroid treatment
[36]. Several authors have suggested the use of a prophy-
lactic anticoagulation (as used in the present subjects) or
replacement therapy with antithrombin concentrates [37].
Evidence-based guidelines for the prevention and treat-
ment for asparaginase-related VTE are lacking, and ran-
domized trials are urgently needed [38].
Another clinical situation in which prophylactic antic-
oagulation seems to be justified is in patients who have
already had a CVC-related VTE. Without prophylactic
anticoagulation, children with CVC-related VTE frequently
experience recurrent catheter complications, including
re-thrombosis (up to 60%), deep vein thrombosis (DVT;
up to 10%), and catheter-associated infections (30%)
[7,39]. The use of prophylactic anticoagulation after CVC-
associated thrombosis or VTE (LMWH or oral anticoagu-
lants) seems to decrease the rate of re-thrombosis [20,21]
and this subject should be discussed and further investi-
gated [35,38,39].
However, the presented study has several limitations
as it is a retrospective study and data were only obtained
by chart review. Therefore only symptomatic thromboses
were diagnosed. Even if we analyzed a time frame of
5 years the number of CVC-associated thromboses was
limited and further diminished by the different types of
malignancies as well as by the different prophylactic and
therapeutic managements as protocols specifying when
to use or not to use antithrombotic prophylaxis are
lacking. Statistical analysis can therefore only provide
trends, which should be confirmed in a greater pro-
spective cohort with uniform protocols and manage-
ment regarding antithrombotic therapy and prophylaxis.
Conclusion
In summary, data about CVC-associated thrombosis and
prophylaxis is scarce, especially for pediatric patients. Evi-
dence from adult patients suggests that routine thrombo-
prophylaxis is not justified, especially with regard to the
side effects in young hyperactive children. Previous studies
emphasize an appropriate catheter position as the most ef-
fective measure to prevent CVC-associated thrombosis.
Beside the vein position, we were not able to define a risk
factor in our oncologic cohort. This may be due to the
multimodal pathophysiologic mechanisms, which will lead
to thrombophilia in those patients. Pediatric surgeons and
oncologists should pay attention to optimal CVC place-
ment and to early symptoms of CVC-related thrombosis
in order to avoid relevant CVC-related complications.
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